Idera Pharmaceuticals Inc (NASDAQ:IDRA) major shareholder Invest Corp Pillar sold 200,000 shares of the company’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $2.40, for a total value of $480,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Invest Corp Pillar also recently made the following trade(s):

  • On Wednesday, December 13th, Invest Corp Pillar sold 1,100,000 shares of Idera Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total value of $2,123,000.00.
  • On Friday, December 15th, Invest Corp Pillar sold 2,300,000 shares of Idera Pharmaceuticals stock. The shares were sold at an average price of $1.96, for a total value of $4,508,000.00.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) traded up $0.15 during trading hours on Friday, reaching $2.55. The company had a trading volume of 2,021,726 shares, compared to its average volume of 1,121,522. The firm has a market capitalization of $468.66, a price-to-earnings ratio of -7.73 and a beta of 2.19. Idera Pharmaceuticals Inc has a 52-week low of $1.30 and a 52-week high of $2.87.

Idera Pharmaceuticals (NASDAQ:IDRA) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.02. The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.20 million. Idera Pharmaceuticals had a negative return on equity of 60.80% and a negative net margin of 313.78%. sell-side analysts predict that Idera Pharmaceuticals Inc will post -0.42 EPS for the current year.

A number of large investors have recently bought and sold shares of IDRA. Rhumbline Advisers raised its position in Idera Pharmaceuticals by 0.3% during the second quarter. Rhumbline Advisers now owns 118,456 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 312 shares during the period. Bank of New York Mellon Corp increased its position in Idera Pharmaceuticals by 0.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 343,761 shares of the biotechnology company’s stock worth $591,000 after purchasing an additional 2,368 shares during the last quarter. Alliancebernstein L.P. increased its position in Idera Pharmaceuticals by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 89,900 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 12,600 shares during the last quarter. Teachers Advisors LLC increased its position in Idera Pharmaceuticals by 12.0% in the 2nd quarter. Teachers Advisors LLC now owns 189,604 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 20,267 shares during the last quarter. Finally, GSA Capital Partners LLP increased its position in Idera Pharmaceuticals by 846.1% in the 2nd quarter. GSA Capital Partners LLP now owns 180,588 shares of the biotechnology company’s stock worth $311,000 after purchasing an additional 161,500 shares during the last quarter. 24.14% of the stock is currently owned by hedge funds and other institutional investors.

IDRA has been the topic of several recent analyst reports. BidaskClub raised Idera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 30th. HC Wainwright set a $4.00 price target on Idera Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 16th. Finally, Zacks Investment Research raised Idera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Thursday, November 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Idera Pharmaceuticals has a consensus rating of “Buy” and an average target price of $4.83.

ILLEGAL ACTIVITY NOTICE: This report was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://theolympiareport.com/2018/01/20/invest-corp-pillar-sells-200000-shares-of-idera-pharmaceuticals-inc-idra-stock.html.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.